The global allergy immunotherapy market size was estimated to be USD 2.78 billion in 2023 and is expected to reach at USD 8.3 billion by 2033 with a CAGR of 10.43% during the forecast period 2023-2033. Rising prevalence of various types of allergies, surge in development of new sublingual immunotherapies, growing exposure to various allergens, increasing investment by market players, rising government support for research & development activities, surge in awareness among population regarding allergies, growing research & development activities, surge in product approvals by regulatory bodies, and increasing introduction of allergy immunotherapy medications are some of the key factors boosting the market growth.
Increasing introduction of allergy immunotherapy medications is predicted to boost the market growth during the forecast period. For instance, in September 2021, Stellargenes Greer has recently unveiled a sublingual immunotherapy tablet in Germany named Orylmyte.
By Type, Subcutaneous immunotherapy (SCIT) was the highest revenue-grossing segment in the global allergy immunotherapy market in 2022 owing to the growing adoption of Subcutaneous immunotherapy (SCIT) due to the high efficacy & cost-effectiveness, rising demand for the treatment of allergic rhinitis, asthma, & stinging insect hypersensitivity, and increasing launch of new products. Additionally, Sublingual Immunotherapy (SLIT) is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of new product due to the benefits associated with the therapy and rising product approvals by regulatory bodies. For instance, in January 2023, The U.S. FDA granted approval to ALK for ODACTRA, a sublingual tablet containing house dust mite allergen extract. This tablet is intended to treat allergic rhinitis induced by house dust mites in individuals between the ages of 12 and 17.
By Application, Allergic rhinitis was the highest revenue-grossing segment in the global allergy immunotherapy market in 2022 owing to the increasing prevalence of allergic rhinitis, surge in development of novel therapies, and increasing product approvals by Food and Drug Administration (FDA). For instance, in April 2021, ALK has made an announcement regarding the approval of RAGWITEK® (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use by the U.S. Food and Drug Administration (FDA). This approval pertains to its use in treating short ragweed pollen-induced allergic rhinitis in individuals aged five to 65 years. Additionally, Allergic asthma is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of asthma, surge in number of patients suffering from asthma, growing investment by market players for the development of AIT drugs for the treatment of various allergies.
By Distribution Channel, Retail & online pharmacies was the highest revenue-grossing segment in the global allergy immunotherapy market in 2022 owing to the high-quality customer service while offering convenience & exclusive savings and growing number of retail pharmacies & patients who purchase medications from these. Additionally, Hospital pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the rising number of hospitals, increasing prevalence of allergic conditions, and surge in number of patients seeking treatment for allergic disorders. For instance, in September 2022, Anaphylaxis UK reports indicate a rise in hospital admissions due to allergies and anaphylaxis between March 2021 and March 2022. Notably, there was a 16.8% increase in admissions for allergy and anaphylaxis among children aged 18 and under when compared to the previous year (2020-2021).
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of allergies, growing awareness of allergy treatment, presence of major market players, and rising product launches. For instance, in January 2020, AR101 (Palforzia) has been approved by the United States Food and Drug Administration, making it the first drug to treat peanut allergy in children. Furthermore, it is effective in mitigating allergic reactions, including anaphylaxis, that may occur following accidental exposure to peanuts. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of patients suffering from different allergies, increasing adoption of novel allergy immunotherapies, growing awareness among people regarding proper management of allergies, and surge in product approvals by regulatory bodies. For instance, in September 2022, Tezspire (tezepelumab) by AstraZeneca has received approval in Japan for treating bronchial asthma in patients with severe or refractory conditions, where asthma symptoms remain uncontrolled despite mid- or high-dose inhaled corticosteroids and other long-term maintenance therapies.
Increasing introduction of allergy immunotherapy medications is predicted to boost the market growth during the forecast period. For instance, in September 2021, Stellargenes Greer has recently unveiled a sublingual immunotherapy tablet in Germany named Orylmyte.
By Type, Subcutaneous immunotherapy (SCIT) was the highest revenue-grossing segment in the global allergy immunotherapy market in 2022 owing to the growing adoption of Subcutaneous immunotherapy (SCIT) due to the high efficacy & cost-effectiveness, rising demand for the treatment of allergic rhinitis, asthma, & stinging insect hypersensitivity, and increasing launch of new products. Additionally, Sublingual Immunotherapy (SLIT) is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of new product due to the benefits associated with the therapy and rising product approvals by regulatory bodies. For instance, in January 2023, The U.S. FDA granted approval to ALK for ODACTRA, a sublingual tablet containing house dust mite allergen extract. This tablet is intended to treat allergic rhinitis induced by house dust mites in individuals between the ages of 12 and 17.
By Application, Allergic rhinitis was the highest revenue-grossing segment in the global allergy immunotherapy market in 2022 owing to the increasing prevalence of allergic rhinitis, surge in development of novel therapies, and increasing product approvals by Food and Drug Administration (FDA). For instance, in April 2021, ALK has made an announcement regarding the approval of RAGWITEK® (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use by the U.S. Food and Drug Administration (FDA). This approval pertains to its use in treating short ragweed pollen-induced allergic rhinitis in individuals aged five to 65 years. Additionally, Allergic asthma is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of asthma, surge in number of patients suffering from asthma, growing investment by market players for the development of AIT drugs for the treatment of various allergies.
By Distribution Channel, Retail & online pharmacies was the highest revenue-grossing segment in the global allergy immunotherapy market in 2022 owing to the high-quality customer service while offering convenience & exclusive savings and growing number of retail pharmacies & patients who purchase medications from these. Additionally, Hospital pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the rising number of hospitals, increasing prevalence of allergic conditions, and surge in number of patients seeking treatment for allergic disorders. For instance, in September 2022, Anaphylaxis UK reports indicate a rise in hospital admissions due to allergies and anaphylaxis between March 2021 and March 2022. Notably, there was a 16.8% increase in admissions for allergy and anaphylaxis among children aged 18 and under when compared to the previous year (2020-2021).
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of allergies, growing awareness of allergy treatment, presence of major market players, and rising product launches. For instance, in January 2020, AR101 (Palforzia) has been approved by the United States Food and Drug Administration, making it the first drug to treat peanut allergy in children. Furthermore, it is effective in mitigating allergic reactions, including anaphylaxis, that may occur following accidental exposure to peanuts. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of patients suffering from different allergies, increasing adoption of novel allergy immunotherapies, growing awareness among people regarding proper management of allergies, and surge in product approvals by regulatory bodies. For instance, in September 2022, Tezspire (tezepelumab) by AstraZeneca has received approval in Japan for treating bronchial asthma in patients with severe or refractory conditions, where asthma symptoms remain uncontrolled despite mid- or high-dose inhaled corticosteroids and other long-term maintenance therapies.
Segmentation: Allergy Immunotherapy Market Report 2022 - 2033
Allergy Immunotherapy Market Analysis & Forecast by Type 2022 - 2033 (Revenue USD Bn)
- Sublingual Immunotherapy (SLIT)
- Subcutaneous Immunotherapy (SCIT)
Allergy Immunotherapy Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Bn)
- Allergic Asthma
- Allergic Rhinitis
- Food Allergy
- Others
Allergy Immunotherapy Market Analysis & Forecast by Distribution Channel 2022 - 2033 (Revenue USD Bn)
- Hospital Pharmacy
- Retail & Online Pharmacies
Allergy Immunotherapy Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Allergy Immunotherapy Market: Type Estimates & Trend Analysis
8. Allergy Immunotherapy Market: Application Estimates & Trend Analysis
9. Allergy Immunotherapy Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Allergy Immunotherapy Market
12. Europe Global Allergy Immunotherapy Market
13. Asia Pacific Global Allergy Immunotherapy Market
14. Latin America Global Allergy Immunotherapy Market
15. MEA Global Allergy Immunotherapy Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Allergy Therapeutics
- ASIT Biotech
- Aimmune Therapeutics
- Mylan N.V.
- Leti Pharma
- Adamis Pharmaceuticals Corporation
- Merck KGaA (Allergopharma)
- DESENTUM OY
- Stallergenes Greer
- HollisterStier Allergy
- ALK-Abello A/S
- LETIPharma
- HAL Allergy Group
- DBV Technologies SA
- Biomay AG
- Circassia
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 2.78 Billion |
| Forecasted Market Value ( USD | $ 8.3 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
